# Excerpt — The 1960 de minimis debate for carcinogens: industry vs. precaution *The Color Additives Amendment hearings (86th Congress, 2d Session, H.R. 7624 / S. 2197, January–February 1960) capture the foundational policy clash over whether carcinogenic food additives can be tolerated below detectable levels. The debate pits industry arguments (natural carcinogens exist at higher levels; zero tolerance is "hysteria") against the scientific consensus (vagueness about carcinogenic dose-response demands precaution). Presiding: Dr. G. Burroughs Mider, NCI Associate Director in Charge of Research, and FDA Commissioner George P. Larrick. Held locally (OCR'd 2026-06-13): `papers/lateral/color-additives-hearing_86thCong_H.R.7624-S.2197_1960.pdf` (+sidecar text). Grade **[CONFIRMED-primary]** (congressional hearing, full text).* --- ## The precautionary case (NAS / Mider / FDA — anti–de minimis) ### **The National Academy of Sciences "vagueness" principle (1960)** From the NAS/NRC Food Protection Committee's Subcommittee on Carcinogenesis, cited in the hearing: > "Because of the **vagueness of present knowledge concerning quantitative aspects of the carcinogenic process**, use of **any amount of a carcinogen as a food additive** probably is justified only if (1) values to the public are such that banning the use would constitute an important loss or hardship, and (2) there is **no reasonably good noncarcinogenic alternative.**" **Implication:** The absence of a known safe threshold = precaution. Carcinogens tolerated only if essential and no substitute exists. --- ### **Dr. G. Burroughs Mider (NCI) on the single-dose / low-dose problem** Mider, presenting the NCI's official cancer research statement to the committee, on why dose-response cannot establish a safe level for carcinogens: > "In the absence of quantitative data, no dose-response relationship can be defined for this situation. It would not be the least bit surprising if a **single dose of carcinogen administered by mouth did elicit cancer in some part of the body.**" And on the dose-accumulation problem: > "Some experimental evidence suggests that the size of the dose of a carcinogen required to produce a cancer is more important than the period of time over which it is given. **Two series of mice received single injections of the carcinogen or repeated injections at monthly intervals.** When the total dose was low the tumor frequency was approximately the same in both groups. Single large doses in increasing amount produced a plateau in the dose-response curve, but **multiple individual doses to the same total dose revealed a steadily progressive increase in carcinogenicity.**" **Implication:** Even tiny repeated doses accumulate; you cannot establish a threshold below which a carcinogen is safe. --- ### **FDA Commissioner George P. Larrick: the stilbestrol ban** On diethylstilbestrol (DES) residues in poultry — Commissioner Larrick's December 1959 decision to ban it entirely: > "It is known to produce a variety of tumors in several species of experimental animals. However, it can do this only after very prolonged administration which in most instances represents approximately one-third of the lifespan of the test animal. In very rare instances, cancers have risen in patients after very prolonged use of stilbestrol, and some physicians have been led to conclude that stilbestrol was a causative factor in these cases. **It would therefore seem desirable to eliminate the hazard, no matter how small, of the prolonged consumption of this material in one's diet from year to year.**" Action taken: > "On the basis of these facts relative to residues of stilbestrol in poultry, I decided to take the following steps: > 1. To request that the authorized manufacturers of stilbestrol for use in poultry immediately suspend the sale of this product. > 2. To request representatives of the poultry industry and the retail food industry to arrange for the immediate discontinuance of the sale of treated birds to consumers." Result (reassurance to the public): > "We were therefore able to reassure the public at the same time we announced our conclusion that stilbestrol should no longer be permitted as a residue in poultry, that the poultry on the market could be **purchased with confidence that it was safe and wholesome.**" **Implication:** Zero tolerance enforced administratively. No "de minimis" exception for carcinogens—even traces are eliminated. --- ### **International consensus (1956 Rome symposium on cancer)** The hearing cites the International Union Against Cancer symposium (Rome, August 1956), where cancer experts from many countries concluded: > "The conference recommends that, as a basis for active cancer prevention, the proper authorities of various countries **promulgate and exact adequate rules and regulations prohibiting the addition to food of substances having potential carcinogenicity.**" --- ## The industry case (de minimis — pro threshold) ### **The argument: natural carcinogens exist at higher levels; regulation should be proportionate** From the industry / pro-flexibility testimony in the same hearing (lines 41566–41600): > "Some compounds which are necessary to normal good health of an animal are also 'carcinogens' as defined by the Delaney amendment. Estrogenic hormones are necessary chemicals which occur naturally in animals and some plants. As defined by the Delaney amendment, they are also carcinogenic. Stilbestrol is a synthetic estrogenic hormone. It is also 'carcinogenic,' by the Delaney amendment definition. **Although estrogenic hormones occur naturally in meat in amounts up to 50 parts per million, sale of caponettes was stopped because stilbestrol was found in some caponette livers at levels up to 0.03 parts per million.** > There are no scientific data which indicate that traces of man-added carcinogens are more harmful than like amounts of carcinogens put there by nature. Neither are there data which indicate minute amounts of 'carcinogenic' chemicals complement each other or accumulate to levels approaching those needed to produce cancer. In fact, there is a lack of scientific data which show that these traces adversely affect the health of any animal in any manner. > **Therefore, legislation requiring zero amounts of these so-called carcinogenic food additives in all human food and animal feed, is not scientifically justified. Such tolerances are based upon fear instead of fact. They reflect hysteria instead of research.**" --- ## Historical context This hearing occurred **before the DES Proviso (1962)**, which rewrote the Delaney Clause to allow carcinogenic animal drugs if "no residue" is detected by approved methods—i.e., the first statutory carcinogen de minimis. The de minimis principle for carcinogens was not law until 1962. In 1960, the precautionary position (Mider, NAS, FDA, international consensus) held regulatory sway. By 1962, the threshold / "undetectable = safe" principle had won a foothold. --- ## Links & relevance **[CONFIRMED-primary]** — Congressional hearing, full text OCR'd. - Pairs with: `sources/Rodricks2019-Crump2018_10-6-origin_excerpt.md` (the carcinogen-side 10⁻⁶ grew from this same threshold debate; Rodricks notes the DES Proviso's reframing of "no residue" as a calculated risk level) - Pairs with: `sources/Kelly_1991_myth-of-10-6_excerpt.md` (officials' confessions that 10⁻⁶ was arbitrary; the de minimis principle itself, in both incarnations, rests on expert discretion / judgment, not science) - Ties to essay: §9 (vinyl chloride as the no-threshold moment; but DES was the *political* threshold moment, even as single-cell carcinogenesis remained unknown) **Register:** D14 (statutory foundation + policy history) --- ## Biographical note on Mider **Dr. G. Burroughs Mider (1906–1985)** — Associate Director in Charge of Research, National Cancer Institute, 1952 onwards. Career pathologist and cancer researcher: fellowship at NCI (1939), instructor and assistant professor of pathology at Cornell Medical College and NY Hospital (1941–44), associate professor at University of Virginia (1944–45), professor of cancer research at University of Rochester (1945–52). Returned to NIH 1952; later served as director of laboratories and clinics (1960–68), acting as deputy director. The NIH's annual G. Burroughs Mider Lecture (established 1968) honors his contributions to biomedical research. In 1960, Mider was a heavyweight: cancer researcher, not bureaucrat, and his testimony on carcinogenic dose-response carried professional authority.